paroxetine has been researched along with substance p in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hill, DR; Stoessl, AJ | 1 |
| Carlson, EJ; Carman, J; Cascieri, MA; Chicchi, GG; Cutler, N; Feighner, J; Hale, JJ; Hargreaves, RJ; Harrison, T; Hefti, F; Hewson, L; Hill, RG; Kramer, MS; Liu, G; MacCoss, M; Mills, SG; Reines, SA; Rupniak, NM; Sadowski, S; Scolnick, EM; Shrivastava, R; Smith, D; Snavely, D; Sramek, JJ; Swain, CJ; Williams, AR; Wyatt-Knowles, E | 1 |
| Nutt, D | 1 |
| Alberti, I; Boni, C; De Felipe, C; Froger, N; Gardier, AM; Hamon, M; Hunt, SP; Jacquot, C; Lanfumey, L; Lena, I; Moratalla, R; Rupniak, NM | 1 |
| Salzman, C | 1 |
| Krishnan, R; Ranga, K | 1 |
| Baghai, TC; Bondy, B; Minov, C; Möller, HJ; Rupprecht, R; Schüle, C; Schwarz, MJ; Zwanzger, P | 1 |
| Berger, M; Fiebich, BL; Grunze, H; Lieb, K; Normann, C; Walden, J | 1 |
| Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F | 1 |
| Alesci, S; Bonne, O; Charney, DS; Collins, C; Gill, JM; Kinkead, B; Luckenbaugh, DA; Manji, HK; Neumeister, A; Owens, MJ; Vythilingam, M; Yuan, P | 1 |
1 review(s) available for paroxetine and substance p
| Article | Year |
|---|---|
Substance P in depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Humans; Paroxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Serotonin; Substance P | 2001 |
6 trial(s) available for paroxetine and substance p
| Article | Year |
|---|---|
Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Topics: Adolescent; Adult; Aged; Amygdala; Animals; Antidepressive Agents, Second-Generation; Aprepitant; Behavior, Animal; Brain; Depressive Disorder; Female; Gerbillinae; Guinea Pigs; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Norepinephrine; Paroxetine; Receptors, Neurokinin-1; Serotonin; Stress, Psychological; Substance P; Vocalization, Animal | 1998 |
Substance-P antagonists: a new treatment for depression?
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance P | 1998 |
Clinical experience with substance P receptor (NK1) antagonists in depression.
Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome | 2002 |
Substance P serum levels are increased in major depression: preliminary results.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Time Factors | 2003 |
Serum levels of substance P and response to antidepressant pharmacotherapy.
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Paroxetine; Severity of Illness Index; Substance P; Surveys and Questionnaires; Triazines | 2004 |
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Dose-Response Relationship, Drug; Gerbillinae; Humans; Male; Neurokinin-1 Receptor Antagonists; Paroxetine; Peptide Fragments; Pyridines; Radioligand Assay; Radionuclide Imaging; Receptors, Neurokinin-1; Stereotyped Behavior; Substance P; Treatment Outcome; Triazoles | 2010 |
3 other study(ies) available for paroxetine and substance p
| Article | Year |
|---|---|
Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide.
Topics: 5,7-Dihydroxytryptamine; Animals; Autoradiography; Brain; Kinetics; Male; Organ Specificity; Paroxetine; Peptide Fragments; Piperidines; Rats; Rats, Inbred Strains; Receptors, Neurotransmitter; Receptors, Tachykinin; Reference Values; Serotonin Antagonists; Substance P; Tachykinins; Tritium | 1990 |
5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Autoreceptors; Drug Resistance; Electrophysiology; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Knockout; Neurons; Paroxetine; Piperazines; Pyridines; Pyrimidines; Raphe Nuclei; Receptors, Neurokinin-1; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Substance P | 2001 |
Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Chronic Disease; Corticotropin-Releasing Hormone; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics; Stress Disorders, Post-Traumatic; Substance P; Treatment Outcome | 2011 |